University of Patras
Διερεύνηση του ρόλου της σηματοδότησης από τις εστιακές συνδέσεις (focal adhesions) στην παθογένεια του καρκίνου του πνεύμονα και του παχέος εντέρου
Abstract
dc:descriptionIntroduction: Lung and colorectal cancer are among the most common types of cancer worldwide in terms of morbidity and mortality. Despite advances in molecular medicine, it is still imperative to find novel predictive and prognostic markers. KRAS mutations are among the most common genetic alterations in lung and colon cancer with prognostic and therapeutic significance. Focal Adhesions (FAs), connect the cell with the ECM through integrins, regulating critical processes implicated in carcinogenesis, such as invasion and metastasis. Integrin-linked kinase (ILK), a serine-threonine kinase located at focal adhesions regulates important cellular functions such as cell migration, survival and EMT and it has been shown to exert an oncogenic role in cancer. ILK has been shown to be overexpressed in many human malignancies and is frequently associated with reduced survival. ILK forms a complex with PINCH and PARVIN family of proteins at FAs-the IPP complex that is critically implicated in integrin and growth factor signaling. The exact role of IPP proteins in human colon and lung cancer is largely unkown. Recent evidence link ILK to KRAS oncogenic functions in pancreatic cancer, and Ras suppressor-1 (RSU1), originally identified as a suppressor of RAS oncogenic functions, has been recently found to interact with the IPP complex regulating cell migration but its exact role in carcinogenesis is not yet clarified. These findings may prove to have major clinical implications in KRAS-driven cancers such as lung adenocarcinoma (LUADC).Aim: To evaluate the role of focal adhesion signaling and especially IPP and RSU1 proteins in human colon and lung cancer. To this end, the role of focal adhesion signaling (IPP complex, RSU1) was examined in colorectal cancer progression in relation to EMT and resistance to chemotherapy and in lung adenocarcinoma development and progression in relation to prognosis, KRAS signaling and EMT. Materials and Methods: We used immunohistochemistry on human colorectal and aenocarcnoma tissue samples and KRAS-driven LUADC in mice, analysis of large scale publicly available RNA sequencing data, ILK overexpression and pharmacologic inhibition of ILK in human colon and lung cancer cell lines, knockdown of KRAS and RSU1 in lung cancer cells, qPCR and immunofluorescence analysis.Results: 1) ILK expression in human CRC correlates with EMT and is associated with chemoresistance. ILK inhibition increases sensitivity of resistant cells to 5-FU and oxaliplatin and reduces the levels of EMT markers in 5-FU resistant cells 2) ILK, PINCH1 and PARVB proteins are overexpressed in human LUADC and KRAS-driven LUADC in mice and represent poor prognostic indicators in the disease. Silencing of KRAS, as well as, overexpression and pharmacological inhibition of ILK in lung cancer cells provide evidence of a two-way association between ILK and KRAS expression in lung cancer cells. Upregulation of PINCH, PARVB and Ras suppressor-1 (RSU1) expression was demonstrated in ILK overexpressing lung cancer cells in addition to a significant positive correlation between these factors in tissue samples, while silencing of KRAS downregulates IPP proteins and RSU1. Pharmacological inhibition of ILK in KRAS mutant lung cancer cells suppresses cell growth, migration, EMT and also increases sensitivity to platinum-based chemotherapy. 3) RSU1 protein expression was associated with favorable prognosis in lung adenocarcinoma while RSU1 depletion promotes cell migration and EMT in human lung cancer cells. Conclusion: ILK promotes an aggressive cancer phenotype with prognostic and therapeutic value through functions that involve KRAS, IPP and RSU1, as well as EMT, rendering ILK a promising biomarker and therapeutic target in cancer. These results suggest that signaling from focal adhesions, is a promising target for precision medicine and evidence-based therapy in cancer.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Nikou, Sofia
- Νίκου, Σοφία
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/48684